Клиническая эффективность и безопасность беклометазона при ХОБЛ (обзор литературы)

1. Brattsand R. Development of inhaled steroids: past, present, and prospects. Respir. Drug Delivery 2002; VIII. www.rddonline.com/pub/01ifa_astraz_brattsand.pdf

2. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.

3. Yildiz F., Kaur A.C., Ildazli A. et al. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 2000; 67: 71-76.

4. Hattotuwa K.L., Gizycki M.J., Ansari T.W. et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am. J. Respir. Crit. Care Med. 2002; 165: 1592-1596

5. Balbi B., Majori M., Bertacco S. et al. Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? Chest 2000; 117: 1633-1637.

6. Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomised, double-blind, placebo controlled study of fluticasone propionate in patients with moderate to severe obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297-1303.

7. Alsaeedi A., Sin D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. 2002; 113: 59-65.

8. van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE Study. Am. J. Respir. Crit. Care Med. 2002; 166: 1358-1363.

9. O'Brien A., Russo-Magno P., Karli A. et al. Effects of with drawal of inhaled steroids in men with severe irreversible air-flow obstruction. Am. J. Respir. Crit. Care Med. 2001; 164: 365-371.

10. Barnes P.J. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 342-344.

11. Gartlehner G., Hansen R.A., Carson S.S., Lohr K.N. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann. Fam. Med. 2006; 4: 253-262.

12. Ulmer W.T. Clinical experience with metered aerosol of beclomethasone in patients with obstructive lung disease. Arzneimittelforschung 1976; 26 (12): 2218-2221.

13. Arossa W., Spinaci S., Testi R. Salbutamol plus beclomethasone dipropionate versus theophylline for the prevention of methacholine-induced bronchospasm in patients with chronic bronchitis. Int. J. Pharmacol. Ther. Toxicol. 1985; 23 (10): 565-568.

14. Thompson A.B., Mueller M.B., Heires A.J. et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am. Rev. Respir. Dis. 1992; 146 (2): 389-395.

15. Weir D.C., Burge P.S. Effects of high inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction. Thorax 1993; 48 (4): 309-316.

16. Nishimura K., Ikeda A., Koyama H. et al. Additive effects of prednisolone and beclomethasone dipropionate in patients with stable chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2000; 13 (5): 225-230.

17. Nishimura K., Koyama H., Ikeda A. et al. The effects of high-dose inhaled beclomethasone dipropionate in patients with stable COPD. Chest 1999; 115 (1): 31-37.

18. John M., Bosse S., Oltmanns U. et al. Effects of inhaled HFA beclomethаsone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir. Med. 2005; 99 (11): 1418-1424.

19. Confalonieri M., Mainardi E., Della Porta R. et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583-585.

20. van Grunsven P.M., van Schayck C.P., Derenne J.P. et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999; 54: 7-14.

21. Derenne J.P. Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. Am. J. Respir. Crit. Care Med. 1995; 151: A463.

22. Kerstjens H.A., Brand P.L., Hughes M.D. et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airway disease. N. Engl. J. Med. 1992; 327: 1413-1419.

23. Renkema T.E., Schouten J.P., Koeter G.H. et al. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109: 1156-1162.

24. Weir D.C., Bale G.A., Bright P. et al. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin. Exp. Allergy 1999; 29 (suppl. 2): 125-128.

25. Douma W.R., Kerstjens A.M., de Gooijer A. et al. Initial improvement in lung function and bronchial hyperresponsiveness are maintained during 5 years of treatment with inhaled beclomethasone dipropionate and terbutaline. Chest 2002; 121 (1): 151-157.

26. Dompeling E., Van Grunsven P.M., Van Schavck C.P. et al. Treatment with inhaled steroids in asthma and chronic bronchitis: long-term compliance and inhaler technique. Fam. Pract. 1992; 9 (2): 161-166.

27. van Beurden W.J., Harff G.A.,.Dekhuijzen P.N. et al. Effects of inhaled corticosteroids with different lung deposition on exhaled hydrogen peroxide in stable COPD patients. Respiration 2003; 70 (3): 242-248.

28. Ferreira I.M., Hazari M.S., Gutierrez C. et al. Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1012-1015.

29. Bourbeau J., Ernst P., Cockcoft D., Suissa S. Inhaled corticosteroids and hospitalisation due to exacerbation of COPD. Eur. Respir. J. 2003; 22: 286-289.

30. Fan V.S., Bryson C.L., Curtis R. et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization. Am. J. Respir. Crit. Care Med. 2003; 168: 1488-1494.

31. Sin D.D., Man S.F.D. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur. Respir. J. 2003; 21: 260-266.

32. Lenney J., Innes J.A., Crompton G.K. Inappropriate inhaler use: assessment of use and patients preference of seven inhalation devices. EDICI. Respir. Med. 2000; 94 (5): 496-500.

33. Kamps A.W., van Ewijk B., Roorda R.J., Brand P.L. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr. Pulmonol. 2000; 29 (1): 39-42.

34. Shrestha M., Parupia H., Andrew B. et al. Metered-dose inhaler technique of patients in an urban ED: prevalence of incorrect technique and attempt at education. Am. J. Emerg. Med. 1996; 14 (4): 380-384.

35. Fink J.B., Rubin B.K. Problems with inhaler use: a call for improved clinician and patient education. Respir. Care 2005; 50 (10): 1360-1374.

36. Price D., Thomas M., Mitchell G. et al. Improvement of asthma control with breath-actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or breath-actuated device. Respir. Med. 2003; 97 (1): 12-19.

37. Haycox A., Mitchell G., Niziol C., Featherstone R. Cost effectiveness of asthma treatment with a breath-actuated pressurised metered dose inhaler (BAI) - a prescribing claims study of 1856 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-actuated device. J. Med. Econom. 2002; 5: 65-77.

38. Ram F.S., Brocklebank D.M., Muers M. et al. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic pulmonary disease. Cochrane Database Syst. Rev. 2002; 1: CD002170.

39. Tattersfield A.E., Harrison T.W., Hubbard R.B., Mortimer K. Safety of inhaled corticiosteroids. Proc. Am. Thorac. Soc. 2004; 1: 171-175.

40. Dinc M., Tchugunova Y., Dinc S. et al. Decreased osteocalcin levels in patients with chronic obstructive pulmonary disease using long-term inhaled beclomethasone dipropionate. Metabolism 2001; 50 (11): 1336-1339.

41. Smeeth L., Boulis M., Hubbard R., Fletcher A.E. A population based case-control study of cataract and inhaled corticosteroids. Br. J. Ophthalmol. 2003; 87: 1247-1251.

42. Cumming R.G., Mitchell P., Leeder S.R. Use of inhaled cor ticosteroids and the risk of cataracts. N. Engl. J. Med. 1997; 337: 8-14.

43. Garbe E., Suissa S., LeLorier J. Association of inhaled cor ticosteroids use with cataract extraction in elderly patients. J. A. M. A. 1998; 280: 539-543.

44. Jick S.S., VasilakisScaramozza C., Maier W.C. The risk of cataract among users of inhaled steroids. Epidemiology 2001; 12: 229-234.

45. Garbe E., LeLorier J., Boivin J.F., Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or openangle glaucoma. J.A.M.A. 1997; 277: 722-727.

46. Mitchell P., Cumming R.G., Mackey D.A. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 1999; 106: 2301-2306.

47. Egan J.J., Maden C., Kalra S. et al. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Eur. Respir. J. 1999; 13: 1267-1275.

48. Tattersfield A.E., Town G.I., Johnell O. et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax 2001; 56: 272-278.

49. Глобальная инициатива по хронической обструктивной болезни легких: Пер. с англ. М.: Атмосфера; 2003.